Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Subscribe

Sci. Signal., 30 July 2013
Vol. 6, Issue 286, p. ra63
[DOI: 10.1126/scisignal.2004177]

RESEARCH ARTICLES

miR-29 Acts as a Decoy in Sarcomas to Protect the Tumor Suppressor A20 mRNA from Degradation by HuR

Mumtaz Y. Balkhi1,2, O. Hans Iwenofu2,3, Nadine Bakkar4, Katherine J. Ladner1,2, Dawn S. Chandler5, Peter J. Houghton5, Cheryl A. London6, William Kraybill2,7, Danilo Perrotti1,2, Carlo M. Croce1,2, Charles Keller8, and Denis C. Guttridge1,2*

1 Department of Molecular Virology, Immunology, and Medical Genetics, Human Cancer Genetics Program, The Ohio State University, Columbus, OH 43210, USA.
2 Arthur G. James Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA.
3 Department of Pathology and Laboratory Medicine, The Ohio State University, Columbus, OH 43210, USA.
4 Barrow Neurological Institute, 350 West Thomas Road, Phoenix, AZ 85013, USA.
5 Center for Pediatric Oncology, Nationwide Children’s Hospital, Columbus, OH 43205, USA.
6 Department of Veterinary Biosciences, College of Veterinary Medicine, The Ohio State University, Columbus, OH 43210, USA.
7 Department of Surgery, The Ohio State University, Columbus, OH 43210, USA.
8 Pediatric Cancer Biology Program, Papé Family Pediatric Research Institute, Oregon Health & Science University, Portland, OR 97239, USA.

Abstract: In sarcoma, the activity of NF-{kappa}B (nuclear factor {kappa}B) reduces the abundance of the microRNA (miRNA) miR-29. The tumor suppressor A20 [also known as TNFAIP3 (tumor necrosis factor–α–induced protein 3)] inhibits an upstream activator of NF-{kappa}B and is often mutated in lymphomas. In a panel of human sarcoma cell lines, we found that the activation of NF-{kappa}B was increased and, although the abundance of A20 protein and mRNA was decreased, the gene encoding A20 was rarely mutated. The 3' untranslated region (UTR) of A20 mRNA has conserved binding sites for both of the miRNAs miR-29 and miR-125. Whereas the expression of miR-125 was increased in human sarcoma tissue, that of miR-29 was decreased in most samples. Overexpression of miR-125 decreased the abundance of A20 mRNA, whereas reconstituting miR-29 in sarcoma cell lines increased the abundance of A20 mRNA and protein. By interacting directly with the RNA binding protein HuR (human antigen R; also known as ELAVL1), miR-29 prevented HuR from binding to the A20 3'UTR and recruiting the RNA degradation complex RISC (RNA-induced silencing complex), suggesting that miR-29 can act as a decoy for HuR, thus protecting A20 transcripts. Decreased miR-29 and A20 abundance in sarcomas correlated with increased activity of NF-{kappa}B and decreased expression of genes associated with differentiation. Together, the findings reveal a unique role of miR-29 and suggest that its absence may contribute to sarcoma tumorigenesis.

* Corresponding author. E-mail: denis.guttridge{at}osumc.edu

Citation: M. Y. Balkhi, O. H. Iwenofu, N. Bakkar, K. J. Ladner, D. S. Chandler, P. J. Houghton, C. A. London, W. Kraybill, D. Perrotti, C. M. Croce, C. Keller, D. C. Guttridge, miR-29 Acts as a Decoy in Sarcomas to Protect the Tumor Suppressor A20 mRNA from Degradation by HuR. Sci. Signal. 6, ra63 (2013).

Read the Full Text


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Emerging roles of miR-210 and other non-coding RNAs in the hypoxic response.
X. Huang and J. Zuo (2014)
Acta Biochim Biophys Sin 46, 220-232
   Abstract »    Full Text »    PDF »

To Advertise     Find Products


Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882